Trial Profile
Randomized Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy (MSK10-134)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Galinpepimut S (Primary) ; Montanide ISA-51; Sargramostim
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- Acronyms MSK10-134
- 31 Jul 2020 Status changed from active, no longer recruiting to completed.
- 09 Mar 2018 Planned End Date changed from 1 Apr 2019 to 1 Apr 2021.
- 09 Mar 2018 Planned primary completion date changed from 1 Apr 2019 to 1 Apr 2020.